The first study to suggest that AMPK was a tumour suppressor used a Eμ-Myc model [163], in which B-cell lymphoma is induced by transgenic over-expression of the Myc oncogene from a B-cell-specific promoter. The gene discussed is PRKAA2; the disease is B-cell non-Hodgkin lymphoma.